Cyclosporine ophthalmic emulsion
Treatment for Dry Eye Disease
Typical Dosage: One drop twice daily in each eye
Effectiveness
85%
Safety Score
75%
Clinical Trials
95
Participants
18K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
75
DangerousModerateSafe
Treatment Details
Dosage Range
One drop twice daily in each eye
Time to Effect
4-12 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$9,000
Monitoring:$600
Side Effect Mgmt:$50
Total Annual:$9,650
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$95,000/QALY
QALYs Gained
0.07
Outcome-Based Costs
Cost per Responder
$14,846
Cost per Remission
$38,600
Comparison vs Artificial Tears
Cost Difference
+$9,050/year
More expensive
QALY Difference
+0.06 QALYs
Better outcomes
Dominance
No dominance
Prescription Access Economics
Annual Societal Loss per Patient
$6,570
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$300/year
Time Cost
$90/year
Travel + wait time
Insurance Admin Cost
$80/year
Prior auth, claims
Rx Price
$9,000/year
Potential OTC Price
$800/year
Estimated if OTC available
Early Treatment Benefit
+0.02 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
LOWMissed Diagnosis Risk
LOWCyclosporine ophthalmic emulsion Outcomes
for Dry Eye Disease
Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+65%
Remission Rate
+25%
Common Side Effects
Ocular burning/stinging
+17%
Eye redness
+5%
Discharge
+3%
Blurred vision
+2%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
18 completed trials for Cyclosporine ophthalmic emulsion in Dry Eye Disease
Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunteers and in Patients With Dry Eye
NCT01319773COMPLETEDPHASE1
44 participants
INTERVENTIONAL
Newport Beach, United States
Started: Nov 1, 2010
Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05%
NCT00827255COMPLETED
35 participants
OBSERVATIONAL
Pittsburgh, United States
Started: Jan 1, 2009
Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease
NCT03597139COMPLETEDPHASE2
100 participants
INTERVENTIONAL
Garden Grove, United States +6 more
Started: Aug 13, 2018
Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease
NCT00717418COMPLETED
781 participants
OBSERVATIONAL
Wilson, United States
Started: Sep 1, 2004
Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis®
NCT02554981COMPLETEDPHASE4
51 participants
INTERVENTIONAL
Andover, United States +1 more
Started: Jul 21, 2015
Effect of Cequa™ in Subjects With Dry Eye Disease
NCT04357795COMPLETEDPHASE4
135 participants
INTERVENTIONAL
Fort Myers, United States +4 more
Started: Jun 29, 2020
Efficacy of Cyclosporine Ophthalmic Emulsion in the Treatment of Dry Eye Syndrome in Contact Lens Wearers
NCT00335114COMPLETEDNA
40 participants
INTERVENTIONAL
Birmingham, United States
Started: Nov 1, 2005
Evaluating HA 0.15% Compared With Cyclosporine 0.05%, and Efficacy of Combination Therapy in Dry Eye Disease Patients
NCT04127851COMPLETEDPHASE4
438 participants
INTERVENTIONAL
Seoul, South Korea
Started: Nov 12, 2019
Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA)
NCT04795752COMPLETEDNA
345 participants
INTERVENTIONAL
Scottsdale, United States +13 more
Started: Apr 28, 2021
Comparing Treatment of Dry Eye With Intracanalicular Dexamethasone, Restasis, and/or Lotemax
NCT04555694COMPLETEDPHASE4
30 participants
INTERVENTIONAL
Brecksville, United States
Started: Oct 1, 2020
A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease
NCT04734197COMPLETEDPHASE2
349 participants
INTERVENTIONAL
Phoenix, United States +39 more
Started: Jan 11, 2021
Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)
NCT01817582COMPLETEDPHASE2
102 participants
INTERVENTIONAL
Irvine, United States
Started: May 17, 2013
CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)
NCT02617667COMPLETEDPHASE2
207 participants
INTERVENTIONAL
Newport Beach, United States +3 more
Started: Jan 1, 2016
NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye
NCT00739349COMPLETEDPHASE2
132 participants
INTERVENTIONAL
Lewiston, United States
Started: Aug 1, 2008
Efficacy and Safety Study of TJCS for Treatment of Moderate to Severe Dry Eye Syndromes
NCT02461719COMPLETEDPHASE3
158 participants
INTERVENTIONAL
Seoul, South Korea
Started: Jan 1, 2014
Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK Patients
NCT00611403COMPLETEDPHASE2
137 participants
INTERVENTIONAL
Overland Park, United States
Started: Dec 1, 2007
Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy
NCT02121847COMPLETEDPHASE4
40 participants
INTERVENTIONAL
Andover, United States
Started: Apr 3, 2014
The Comparison of 50% AS Versus PFAT+ 0.05 % COE in Severe Dry Eye Syndrome
NCT03666884COMPLETEDPHASE4
36 participants
INTERVENTIONAL
Started: Oct 10, 2015
Showing 20 of 98 total trials